Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19, and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection, and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence (AI) and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene this process does not work as well, and lung cells are left vulnerable to infection by the virus.
The researchers noted that it is particularly important to offer vaccination to communities that are at greater risk of serious COVID-19 infection as a consequence of carrying this genetic predisposition, as their increased risk should be cancelled out by immunisation.
Independent experts said the findings are very important but warrant further investigation.
&ldquo;The discrepancy between the risk of serious disease and death in different ethnic groups has previously been attributed in part to socio-economic&nbsp;differences, but it was clear that this was not a complete explanation," said Professor Frances Flinter, from Guy&rsquo;s &amp; St Thomas&rsquo; NHS Foundation Trust, UK.
&ldquo;Evidence that LZTFL1 has emerged as a candidate causal gene, which is potentially responsible for some of the two-fold increased risk of respiratory failure from COVID-19 in some populations, provides a big step forward in our understanding of the variable susceptibility&nbsp;of some individuals to serious disease and death,&rdquo; Flinter, who was not involved in the study, added.
Simon Biddie, from the University of Edinburgh, UK, said the study provides compelling evidence to suggest roles for LZFTL1 in severe COVID-19 that warrants urgent further investigation.
&ldquo;The finding will need further experimental verification to provide direct evidence for regulation of LZTFL1, using for example genome engineering approaches," Biddie, who was not a part of the study, added.

Oxford-led study: gene common in South Asians may double risk of Covid-19 death

Oxford-led study: gene common in South Asians may double risk of Covid-19 death. Here is more.

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19 and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene, this process does not work as well, and lung cells are left vulnerable to infection by the virus.
Independent experts said the findings are very important but warrant further investigation.
&nbsp;

The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said

Scientists at the University of Oxford have identified a gene that may double the risks of lung failure and death from COVID-19, and could explain why people of South Asian ancestry have a higher risk of severe disease.
The LZTFL1 gene changes the way the lungs respond to viral infection and is the most important genetic risk factor identified so far, the researchers said.
They noted that the gene version is carried by nearly 60 per cent of people with South Asian background, compared with 15 per cent of those with European lineage.
Also watch |&nbsp;<a href="https://www.editorji.com/india-news/coronavirus-how-do-covid-19-boosters-work-and-are-they-same-as-the-original-vaccines-1636079209378" target="_blank">Coronavirus: How do Covid-19 boosters work and are they same as the original vaccines?</a>
The finding, published in the journal Nature Genetics on Thursday, could also partly explain the impact of COVID-19 in the Indian subcontinent.
The researchers used a combination of artificial intelligence (AI) and new molecular technology to pinpoint LZTFL1 as a gene responsible for the increased risks.
LZTFL1 blocks a key protective mechanism that cells lining the lungs normally use to defend themselves from the viral infection, they said.
When these cells interact with SARS-CoV-2, which causes COVID-19, one of their defence strategies is to turn into less specialised cells and become less welcoming to the virus.
This process reduces the amount on the surface of cells of a key protein called ACE2, which the coronavirus uses to attach itself to the cells.
However, for people with the LZTFL1 gene this process does not work as well, and lung cells are left vulnerable to infection by the virus.
The researchers noted that it is particularly important to offer vaccination to communities that are at greater risk of serious COVID-19 infection as a consequence of carrying this genetic predisposition, as their increased risk should be cancelled out by immunisation.
Independent experts said the findings are very important but warrant further investigation.
&ldquo;The discrepancy between the risk of serious disease and death in different ethnic groups has previously been attributed in part to socio-economic&nbsp;differences, but it was clear that this was not a complete explanation," said Professor Frances Flinter, from Guy&rsquo;s &amp; St Thomas&rsquo; NHS Foundation Trust, UK.
&ldquo;Evidence that LZTFL1 has emerged as a candidate causal gene, which is potentially responsible for some of the two-fold increased risk of respiratory failure from COVID-19 in some populations, provides a big step forward in our understanding of the variable susceptibility&nbsp;of some individuals to serious disease and death,&rdquo; Flinter, who was not involved in the study, added.
Simon Biddie, from the University of Edinburgh, UK, said the study provides compelling evidence to suggest roles for LZFTL1 in severe COVID-19 that warrants urgent further investigation.
&ldquo;The finding will need further experimental verification to provide direct evidence for regulation of LZTFL1, using for example genome engineering approaches," Biddie, who was not a part of the study, added.

Brazil: Oxford Covid vaccine trial volunteer dies 

Brazilian health authority said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University has died

Brazilian health authority said on Wednesday that a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University has died, news agency Reuters has reported. The regulator said testing of the vaccine would continue after the volunteer's death. It provided no further details, citing medical confidentiality of those involved in trials, the report added. The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said that the volunteer was Brazilian but did not say where the person lived.

Covid vaccine trial pause a wake-up call: WHO

The World Health Organisation has said that the pause on the trials of the Oxford Covid vaccine is a "wake-up call", but&nbsp; it should "not discourage researchers"

The World Health Organisation has said that the pause on the trials of the Oxford Covid vaccine is a "wake-up call". The world body, however, added that it should not discourage researchers. "This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," WHO chief scientist Soumya Swaminathan told a virtual briefing from Geneva. Pharma giant AstraZeneca suspended late-stage trials of vaccine this week after a participant in Britain suffered from neurological symptoms.

oxford covid

Categories